Tanya Dorff, MD, of City of Hope, shares the key takeaways from the Uromigos Live & Unplugged 2024, and talks about how androgen deprivation therapy (ADT) remains the cornerstone of care, even as new therapies like radioligands and androgen receptor inhibitors are introduced. With insights from the latest trials, including the EMBARK trial, Dr. Dorff discusses the benefits of combining ADT with doublet therapy and the ongoing challenges of managing long-term side effects.
Uromigos Live 2024 Highlights: The Evolving Role of ADT in Prostate Cancer
By Tanya Dorff, MD - Last Updated: October 10, 2024Related Posts
Enzalutamide with [177Lu]Lu-PSMA-617 improved OS and HRQOL, along with PSA PFS.
Dr. Tan discusses the TALAPRO-2 study, PARP inhibitor synergy, HRR testing, and evolving treatment strategies in mCRPC.
The combination demonstrated a manageable safety profile with evidence of EZH2 pharmacodynamic inhibition and OR.
Final TALAPRO-2 results show talazoparib + enzalutamide significantly improves survival in patients with HRR-deficient mCRPC.
New research sheds light on the real-world outcomes of Lu-PSMA-617 in a racially diverse patient population.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.